Currently, inhibitors of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are well known and have been approved for several cancer treatments. Here, PDCD1 is linked to cancer.